Kisspeptin-10 — compound monograph
Endogenous decapeptide, KISS1 receptor agonist. Unapproved, research supply. The Institute assesses 3 outcomes for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Kisspeptin-10
- Compound class
- Endogenous decapeptide, KISS1 receptor agonist
- Assessment series
- Reproductive-axis peptides
- Synonyms and codes
- metastin(45-54) · KP-10 · kisspeptin-54 C-terminal decapeptide
- Route as evaluated
- Intravenous infusion and subcutaneous in clinical research
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 374675-21-5
- Molecular formula
- C63H83N17O14
- Average mass
- 1302.45
- Monoisotopic mass
- 1301.63
- ATC classification
- not assigned
§1.3Sequence and structural notes
The C-terminal decapeptide of kisspeptin-54, retaining full receptor activity. The C-terminal amide and the Arg-Phe-NH₂ motif are essential for receptor binding. It contains a tryptophan and two asparagines, making it both oxidation- and deamidation-labile.
§1.4Assessment status
The Institute assesses Kisspeptin-10 across 3 indications and grades the strongest of them at low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for Kisspeptin-10, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | Diagnostic use as a probe of hypothalamic-pituitary-gonadal function | Moderate | 0 |
| Hypoactive sexual desire and erectile dysfunction | Small randomised crossover studies in men with hypoactive sexual desire reported changes in limbic activation on functional imaging and in… | Low | 1 |
| Polycystic ovary syndrome | Kisspeptin-54 has been used as an oocyte-maturation trigger in assisted reproduction with reported reduction in ovarian hyperstimulation risk… | Low | 2 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.